Meeting
2021 ASCO Annual Meeting
Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.
Authors
Wei Fang Dai
University of Toronto, Toronto, ON, Canada
Wei Fang Dai , Jaclyn Marie Beca , Chenthila Nagamuthu , Ning Liu , Maureen E. Trudeau , Craig Earle , Claire De Oliveira , Kelvin K. Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1048)
DOI
10.1200/JCO.2021.39.15_suppl.1048
Abstract #
1048
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
Poster
2023 ASCO Annual Meeting
Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer.
First Author: James Dickerson
Poster
2011 ASCO Annual Meeting
The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
First Author: A. J. Montero
Poster
2024 ASCO Annual Meeting
A single center retrospective cohort study of patients with metastatic breast cancer and leptomeningeal disease: Updated survival data and subgroup analyses by breast cancer subtype.
First Author: Samantha Catherine Fisch